Table 2.

Survival and progression characteristics as a function of T790M mutation status

T790M positive (n = 58)T790M negative (n = 35)P
Median postprogression survival, mo19 (16–24)12 (8–17)0.036
KPS at progression0.007
 80%–90%53 (91%)26 (74%) 
 60%–70%5 (9%)4 (11%)
 30%–50%0 (0%)5 (14%)
Site of disease progression0.014
 New metastatic organ system involved6 (10%)11 (31%) 
 Existing organ only52 (90%)24 (69%)
Median time from progression to new metastatic organ involvement, moa14 (8–18)4 (1–9)0.008
TKI continued after progression0.32
 Yes53 (91%)29 (83%) 
 No5 (9%)6 (17%)
Treated with chemotherapy subsequently0.31
 Yes47 (81%)35 (71%) 
 No11 (19%)10 (29%)
Treated on clinical trial subsequently0.39
 Yes28 (48%)13 (37%) 
 No30 (52%)22 (63%)

aSee Methods for detailed definition.